Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?
In this article, an approach to the diagnostic evaluation of patients with newly diagnosed advanced NSCLC is suggested, in an attempt to identify the best treatment options. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Apar Kishor Ganti, MD, MS Source Type: news

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Phase 1/2 clinical trial in patients with advanced solid tumors that have progressed on anti-PD-1/PD-L1 therapy to evaluate APX005M in combination with cabiralizumab and Opdivo Study to enroll metastatic non-small cell lung cancer (NSCLC), metastatic me... Biopharmaceuticals, Oncology Apexigen, cabiralizumab, Opdivo, NSCLC, melanoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2018 Category: Pharmaceuticals Source Type: news

Newer Targeted Agents in NSCLC: ALK Inhibitors
Alice Shaw highlights the development and clinical considerations for use of first- and next-generation ALK inhibitors in NSCLC, plus ongoing research. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2018 Category: Cancer & Oncology Authors: Alice T. Shaw, MD, PhD Source Type: news

NSCLC: Nivolumab Extends 5-Year Survival in Heavily Pretreated Patients
(MedPage Today) -- In phase I study, no evidence of progression or need for subsequent therapy in 12 of 16 patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Improved OS With Dacomitinib vs Gefitinib in Selected EGFR+ NSCLC
Researchers in Hong Kong found dacomitinib was associated with longer OS than gefitinib in patients with advanced EGFR+ NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Avelumab Plus Lorlatinib Active in ALK+ NSCLC
An avelumab combination therapy shows promise against ALK-driven lung cancers, but another was not safe or effective against non –ALK-driven cases. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
In this video,Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2018 Category: Cancer & Oncology Authors: Apar Kishor Ganti, MD, MS Source Type: news

Flagship Biosciences Co-Publishes PD-L1 Immunohistochemistry Research...
First NSCLC study using cTA to report IHC data in immuno-oncology(PRWeb June 07, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15537608.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 7, 2018 Category: Pharmaceuticals Source Type: news

Exploring the Changing Landscape of ICI Tx in NSCLC
Leena Gandhi, MDJun 6, 2018In this video,Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study
Adding atezolizumab to a combination of bevacizumab, carboplatin and paclitaxel gives patients with metastatic nonsquamous non-small-cell lung cancer better odds of progression-free and overall survival, a new study of 692 patients with wild-type disease has concluded.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
New approval based on KEYNOTE-021, Cohort G1, results INDIANAPOLIS, June 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a ... Biopharmaceuticals, Oncology, FDA Eli Lilly, ALIMTA, pemetrexed, KEYTRUDA, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2018 Category: Pharmaceuticals Source Type: news

NSCLC Survival Rises with Checkpoint Blocker Add-On
(MedPage Today) -- Atezolizumab plus standard therapy also slows disease progression (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 4, 2018 Category: Primary Care Source Type: news

ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC
Improved overall survival versus chemotherapy regardless of the PD - L1 tumor proportion score (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 4, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Conference News, Source Type: news

Keytruda Alone Bests Chemo in Advanced NSCLC
(MedPage Today) -- Monotherapy boosts survival in patients with low PD-L1, no EGFR or ALK alterations (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 4, 2018 Category: Hematology Source Type: news

ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC
MONDAY, June 4, 2018 -- For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

Pembrolizumab Bests Chemotherapy in PD-L1 Expressing NSCLC
John SchieszerJun 3, 2018Pembrolizumab represents a new standard first-line treatment option for PD-L1 –expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Pembrolizumab Bests Chemotherapy in PD-L1 –Expressing NSCLC
John SchieszerJun 3, 2018Pembrolizumab represents a new standard first-line treatment option for PD-L1 –expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

' End of an Era' for Chemo in Non-Small Cell Lung Cancer'End of an Era' for Chemo in Non-Small Cell Lung Cancer
The fear of unsupportable adverse effects from chemotherapy can be laid to rest for most patients with non-small cell lung cancer, say experts at the world's largest cancer meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival
Bryant FurlowJun 3, 2018Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Is Pembrolizumab Appropriate Before EGFR TKI Therapy in Lung Cancer?
Bryant FurlowJun 3, 2018Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

ASCO18: Updated Phase 1 results of crizotinib against MET-amplified lung cancer
(University of Colorado Anschutz Medical Campus) By lowering the bar for 'high MET amplification,' a study suggests that crizotinib may benefit more MET-amplified non-small cell lung cancer patients than previously thought. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2018 Category: Cancer & Oncology Source Type: news

ASCO: ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
(University of Colorado Anschutz Medical Campus) Updated data presented at ASCO 2018 further consolidate alectinib as the standard-of-care for first-line treatment of ALK+ non-small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2018 Category: Cancer & Oncology Source Type: news

Checkpoint Blocker Plus Chemo Slows NSCLC Progress
(MedPage Today) -- No significant OS improvement in interim analysis of IMpower131 trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2018 Category: Hematology Source Type: news

PFS Boost With Atezolizumab in Advanced Squamous NSCLC
Bryant FurlowJun 2, 2018The addition of atezolizumab to chemotherapy was associated with superior PFS but did not improve preliminary OS. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Media News)
Source: Roche Media News - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2018 Category: Pharmaceuticals Source Type: news

Cleveland Clinic Cancer Center experts present data at 2018 ASCO Annual Meeting
(Cleveland Clinic) At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells' response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

Top 5 Advanced NSCLC Presentations at ASCO 2018 Top 5 Advanced NSCLC Presentations at ASCO 2018
Thoracic oncologist Dr Jack West discusses the five most important and clinically relevant abstracts to be presented at the upcoming ASCO 2018 annual meeting.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - May 29, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - May 29, 2018 Category: Pharmaceuticals Source Type: news

Combining Proton Beam Therapy and Immunotherapy Combining Proton Beam Therapy and Immunotherapy
Are outcomes improved in patients with NSCLC receiving both proton beam therapy and immunotherapy?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Time to'Rethink' Immunotherapy for Molecularly Driven NSCLC Time to'Rethink' Immunotherapy for Molecularly Driven NSCLC
Drs West and Borghaei discuss IMpower150 and why clinicians should reconsider using immunotherapy as a last line of defense in molecularly driven NSCLC.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Trial'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer Trial'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer
Thoracic oncologists Drs Jack West and Hossein Borghaei discuss critical questions in the treatment of low-expressing or PD-L1-negative non-small cell lung cancer patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC
While KEYNOTE-189 answered many questions about immuno-oncology for NSCLC, Drs West and Borghaei look forward to results of KEYNOTE-042 for even more answers.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Most Efficient, Less Costly Gene Testing Method for NSCLC Most Efficient, Less Costly Gene Testing Method for NSCLC
For genetic testing of patients with non-small cell lung cancer (NSCLC), next-generation sequencing is less costly than other methods, and results are available much sooner.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Follow-up phase III data showed Roche ’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death
Roche today announced follow-up data from the phase III ALEX study, showing that, as an initial treatment, Alecensa ® (alectinib) significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 57% (hazard ratio [HR]= 0.43, 95% CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-sm all cell lung cancer (NSCLC), as assessed by the investigator. (Source: Roche Media News)
Source: Roche Media News - May 17, 2018 Category: Pharmaceuticals Source Type: news

Follow-up phase III data showed Roche ’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death
Roche today announced follow-up data from the phase III ALEX study, showing that, as an initial treatment, Alecensa ® (alectinib) significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 57% (hazard ratio [HR]= 0.43, 95% CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-sm all cell lung cancer (NSCLC), as assessed by the investigator. (Source: Roche Investor Update)
Source: Roche Investor Update - May 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 17, 2018 Category: Pharmaceuticals Source Type: news

Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients? Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients?
Thoracic oncologists Drs Jack West and Hossein Borghaei talk about when to add chemotherapy to immunotherapy in high PD-L1-expressing non-small cell lung cancer patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Upfront, comprehensive genetic testing in advanced lung cancer is cost-effective
(American Society of Clinical Oncology) An economic model comparing different types of genetic testing in metastatic non-small-cell lung cancer (NSCLC) found that using next-generation sequencing (NGS) to test for all known lung cancer-related gene changes at the time of diagnosis was more cost-effective and faster than testing one or a limited number of genes at a time. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

' Reality Check': How NSCLC Treatment Differs in UK vs US'Reality Check': How NSCLC Treatment Differs in UK vs US
A comparison of patients with lung cancer from England and the United States shows distinct patterns in diagnosis, treatment, and outcomes that perhaps reflect cultural differences toward aggressive management.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Osimertinib Improves Patient-Reported Outcomes in Advanced NSCLC
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
This research article has led to a Practice Update in DynaMed Plus. It concludes that addition of pembrolizumab to chemotherapy with pemetrexed and platinum-based drug increases overall survival in patients with previously untreated metastatic nonsquamous non-small cell lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 9, 2018 Category: Consumer Health News Source Type: news

FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - May 8, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New biomarker identified for early diagnosis of lung cancer
(Elsevier) In a novel study in The American Journal of Pathology investigators found that CKAP4 levels were significantly higher in patients with lung cancer than in healthy individuals. They further determined that CKAP4 levels are already elevated in the blood of patients with stage I disease, making it a potential noninvasive diagnostic marker that could change current practices in the diagnosis and treatment of some types of lung cancer, including non-small-cell lung cancer and squamous cell carcinoma, and improve patient outcomes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2018 Category: Biology Source Type: news

Genprex Announces $10 Million Private Placement
AUSTIN, Texas, May 7, 2018 -- (Healthcare Sales & Marketing Network) -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today th... Biopharmaceuticals, Oncology, Venture Capital Genprex, Oncoprex, immunogene therapy, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 7, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 7, 2018 Category: Pharmaceuticals Source Type: news